Type 2 immune response mediators

Type 2 immune response mediators refer to a group of cytokines and signaling proteins, including Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13), and upstream alarmins like Thymic Stromal Lymphopoietin (TSLP), that orchestrate allergic and eosinophilic inflammation (Gandhi et al., 2016, PMID: 26471366). These mediators are primarily produced by Th2 cells, type 2 innate lymphoid cells (ILC2s), and mast cells to coordinate host defense against parasites, but their dysregulation leads to chronic inflammatory diseases (Fahy, 2015, PMID: 25554354). In conditions like severe asthma and atopic dermatitis, these molecules promote eosinophil recruitment, IgE production, and tissue remodeling. Therapeutic strategies involve monoclonal antibodies that neutralize these cytokines or block their receptors, such as Dupilumab (targeting IL-4Rα) and Mepolizumab (targeting IL-5) (Corren, 2019, PMID: 31005515). These treatments are particularly effective in patients identified by biomarkers like high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO).

Other names

Type 2 cytokinesTh2 cytokinesType 2 inflammatory mediatorsType 2 immune pathway

Drugs targeting these mediators function by neutralizing specific cytokines (e.g., IL-5, IL-13, TSLP) or blocking their receptors (e.g., IL-4Rα, IL-5Rα) to prevent the activation of downstream signaling pathways like JAK-STAT, thereby reducing eosinophil survival, IgE class switching, and tissue remodeling (Gandhi et al., 2016, PMID: 26471366).